Published in Clin J Am Soc Nephrol on March 01, 2008
Cidofovir in Renal Transplant Recipients With BKVN | NCT00138424
The impact of recipient BKV shedding before transplant on BKV viruria, DNAemia, and nephropathy post-transplant: A prospective study. Pediatr Transplant (2017) 1.40
Human polyoma viruses and disease with emphasis on clinical BK and JC. J Clin Virol (2010) 1.17
Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol (2010) 1.04
Recent developments in kidney transplantation--a critical assessment. Am J Transplant (2009) 1.02
Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol (2012) 0.95
Frequency of Polyomavirus BK Infection in Kidney Transplant Patients Suspected to Nephropathy. Int J Organ Transplant Med (2015) 0.83
BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol (2013) 0.80
Place of mTOR inhibitors in management of BKV infection after kidney transplantation. J Nephropathol (2015) 0.80
Mechanisms of BK virus infection of renal cells and therapeutic implications. J Clin Virol (2015) 0.76
Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia. Transpl Infect Dis (2015) 0.76
Polyomavirus-Specific Cellular Immunity: From BK-Virus-Specific Cellular Immunity to BK-Virus-Associated Nephropathy? Front Immunol (2015) 0.75
Gene therapy to the kidney using viral vectors. Paidiatrike (2008) 0.75
Incidence of BK Virus Nephropathy (BKVN) in Renal Transplant Recipients. Int J Organ Transplant Med (2012) 0.75
BK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Am J Nephrol (2013) 0.75
BK virus nephropathy is not always alone. J Renal Inj Prev (2015) 0.75
Clinical Pharmacokinetic Monitoring of Leflunomide in Renal Transplant Recipients with BK Virus Reactivation: A Review of the Literature. Clin Pharmacokinet (2017) 0.75
New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet (1971) 12.13
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Noninvasive diagnosis of BK virus nephritis by measurement of messenger RNA for BK virus VP1 in urine. Transplantation (2002) 2.86
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant (2005) 2.76
Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med (2000) 2.63
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant (2005) 2.19
Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant (2007) 2.15
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Infection of vero cells by BK virus is dependent on caveolae. J Virol (2004) 1.77
Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation (1999) 1.71
Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant (2004) 1.64
Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant (2003) 1.64
Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Am J Kidney Dis (1997) 1.59
Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol (2006) 1.58
Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant (2002) 1.55
BK virus nephritis after renal transplantation. Kidney Int (2006) 1.54
Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia. Am J Transplant (2006) 1.47
Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation (2003) 1.47
Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant (2006) 1.42
BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med (2001) 1.41
Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol (1999) 1.39
Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation (2006) 1.38
BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int (2005) 1.34
Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein. J Immunol (1998) 1.32
BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis (1995) 1.28
T-cell responses to peptide fragments of the BK virus T antigen: implications for cross-reactivity of immune response to JC virus. J Gen Virol (2006) 1.27
Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides. J Virol (2005) 1.26
Leflunomide for polyomavirus type BK nephropathy. N Engl J Med (2005) 1.25
Caveolar endocytosis is critical for BK virus infection of human renal proximal tubular epithelial cells. J Virol (2007) 1.24
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology (1999) 1.23
Polyomavirus BK-specific immunity after kidney transplantation. Transplantation (2004) 1.22
Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation (2006) 1.20
Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant (2005) 1.10
Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant (2005) 1.09
Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int (2003) 1.08
Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant (2003) 1.08
Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation (2003) 1.06
Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. Transplantation (2001) 1.01
Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant (2004) 1.00
HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant (2004) 0.99
Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med (2006) 0.95
Detection of CD8+ T cells sensitized to BK virus large T antigen in healthy volunteers and kidney transplant recipients. Hum Immunol (2006) 0.95
Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol (2007) 0.94
Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation (2008) 0.89
Cost efficiency in the prospective diagnosis and follow-up of polyomavirus allograft nephropathy. Transplant Proc (2004) 0.89
Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome. Transplant Proc (2007) 0.89
Tubular basement membrane immune deposits in association with BK polyomavirus nephropathy. Am J Transplant (2007) 0.88
Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clin Transplant (2002) 0.87
Negative impact of human leukocyte antigen matching in the outcome of polyomavirus nephropathy. Transplantation (2005) 0.86
Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender. Kidney Int (2007) 0.83
Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation (2004) 0.83
BK polyoma virus nephropathy in kidney transplant recipient: the role of new immunosuppressive agents. Transplant Proc (2003) 0.83
Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transplant (2004) 0.81
BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant (2004) 0.80
Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients. Clin Transplant (2007) 0.78
Remission of polyomavirus-induced graft nephropathy treated with low-dose leflunomide. Nephrol Dial Transplant (2006) 0.78
Delayed renal allograft dysfunction and cystitis associated with human polyomavirus (BK) infection in a renal transplant recipient: a case report and review of literature. Clin Nephrol (2003) 0.77
Immunocytological urinalysis and monocyte chemotactic peptide-1 in renal transplant recipients with polyomavirus replication. Transplant Proc (2006) 0.76
Relationship of HLA-DR expression to rejection and mononuclear cell infiltration in renal allograft biopsies. Ren Fail (2004) 0.76
Pathogenesis of BK virus infection after renal transplantation. Expert Rev Clin Immunol (2006) 0.76
HLA-DR class II and ICAM-1 expression on tubular cells taken by fine-needle aspiration biopsy in renal allograft dysfunction. Nephrol Dial Transplant (1996) 0.76
Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation (2002) 3.41
The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant (2001) 1.88
Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int (2002) 1.63
Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol (2002) 1.57
A comparison between recipients receiving matched kidney and those receiving mismatched kidney from the same cadaver donor. Am J Transplant (2002) 1.45
BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int (2005) 1.34
Cancer after renal transplantation. Curr Opin Nephrol Hypertens (2007) 1.05
Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation (2008) 1.05
Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int (2004) 1.01
Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation (2007) 1.01
Rhodococcus equi pneumonia in a renal transplant patient: a case report and review of literature. Clin Transplant (2004) 0.99
Access to kidney transplantation among patients insured by the United States Department of Veterans Affairs. J Am Soc Nephrol (2007) 0.95
Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation (2012) 0.92
Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol (2008) 0.91
Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation (2008) 0.89
Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab. Clin Transplant (2005) 0.88
Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. Clin Transplant (2002) 0.87
Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant (2003) 0.86
Percussion hemoglobinuria - a novel term for hand trauma-induced mechanical hemolysis: a case report. J Med Case Rep (2011) 0.86
A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol (2006) 0.85
The advanced age deceased kidney donor: current outcomes and future opportunities. Kidney Int (2005) 0.84
Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation. Transplantation (2016) 0.81
Immunomodulation in stable renal transplant recipients with concomitant tacrolimus and sirolimus therapy. Med Immunol (2002) 0.81
Improvements in long-term renal transplant graft survival. Am J Transplant (2005) 0.81
Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol (2005) 0.81
Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. Transplantation (2013) 0.79
Subclinical Rejection in Renal Transplantation: Reappraised. Transplantation (2016) 0.77
Lower prevalence of BK virus infection in African American renal transplant recipients: a prospective study. Transplantation (2012) 0.77
Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation (2011) 0.77
A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int (2017) 0.76
Pathogenesis of BK virus infection after renal transplantation. Expert Rev Clin Immunol (2006) 0.76
Declining rates of deceased donor renal transplantation in the United States over successive years of listing. Am J Med (2012) 0.75
Case 5: new clinical trials in renal transplantation. Transplantation (2003) 0.75
Case 4: cardiovascular risk in renal transplantation. Transplantation (2003) 0.75
Benefit of child-to-parent kidney donation. Am J Transplant (2003) 0.75
FGF-23 Klotho Axis: Will Intervention Improve Kidney Transplant Outcomes? Transplantation (2016) 0.75
Donor kidney microthrombi and outcomes of kidney transplant: a single-center experience. Clin Transplant (2015) 0.75
Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). Transplantation (2002) 0.75
A Simpler Blood Test for Monitoring Kidney Transplant Recipients: "A Disrupting Innovation". Transplantation (2017) 0.75
Case 3: new clinical trials in renal transplantation. Transplantation (2003) 0.75